To experimentally test the hypothesis that disruption of IDO1 impacts both tryptophan and kynurenine pool sizes, we used CRISPR–Cas9-mediated knockout with single-guide RNAs (sgRNAs) targeted against IDO1 human colorectal carcinoma HCT116 cells. This evidence concerns the gene IDO1 and colorectal carcinoma.